How paediatric drug development and use could benefit from OMICs: A c4c expert group white paper

Neumann, Eva; Schreeck, Filippa; Herberg, Jethro; Jacqz Aigrain, Evelyne; Maitland-van der Zee, Anke H.; Pérez-Martínez, Antonio; Hawcutt, Daniel B.; Schäffeler, Elke; Rane, Anders; de Wildt, Saskia N.; Schwab, Matthias

dc.contributor.author	Neumann, Eva
dc.contributor.author	Schreeck, Filippa
dc.contributor.author	Schäffeler, Elke
dc.contributor.author	Schwab, Matthias
dc.date.accessioned	2024-09-25T08:50:39Z
dc.date.available	2024-09-25T08:50:39Z
dc.date.issued	2022
dc.identifier.issn	0264-3774
dc.identifier.uri	http://hdl.handle.net/10900/157695
dc.language.iso	en	de_DE
dc.publisher	Oxford: Wiley-Blackwell	de_DE
dc.relation.uri	https://dx.doi.org/10.1111/bcp.15216	de_DE
dc.subject.ddc	610	de_DE
dc.title	How paediatric drug development and use could benefit from OMICs: A c4c expert group white paper	de_DE
dc.type	Article	de_DE
utue.publikation.seiten	5017-5033	de_DE
utue.personen.roh	Neumann, Eva
utue.personen.roh	Schreeck, Filippa
utue.personen.roh	Herberg, Jethro
utue.personen.roh	Jacqz Aigrain, Evelyne
utue.personen.roh	Maitland-van der Zee, Anke H.
utue.personen.roh	Pérez-Martínez, Antonio
utue.personen.roh	Hawcutt, Daniel B.
utue.personen.roh	Schäffeler, Elke
utue.personen.roh	Rane, Anders
utue.personen.roh	de Wildt, Saskia N.
utue.personen.roh	Schwab, Matthias
dcterms.isPartOf.ZSTitelID	British journal of Clinical Pharmacology	de_DE
dcterms.isPartOf.ZS-Issue	12	de_DE
dcterms.isPartOf.ZS-Volume	88	de_DE